All In MedTech

FDA Clearance Tracker · K111047

CELLVIZIO 100 SERIES SYSTEM WITH CONFOCAL MINIPROBES

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Aug 8, 2011 (this decision)Source: openFDAMethods & limitations

510(k)First of its product codeThird-party review

Decided

Aug 8, 2011

Substantially Equivalent

Time to decision

115 days

Received Apr 15, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Special

Device class

Class II

The decision

FDA number
K111047
Device name
CELLVIZIO 100 SERIES SYSTEM WITH CONFOCAL MINIPROBES
Applicant location
Newton, PA
Received
Apr 15, 2011
Decided
Aug 8, 2011
Decision
Substantially Equivalent
Submission type
Special
Third-party review
Yes. An FDA-accredited third party reviewed this submission before FDA decided.

Device type

Device class
Class II
Regulation
21 CFR 876.1500

Every decision under product code OWN

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OWN (Confocal Optical Imaging).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Mauna Kea Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.